- Home
- USGO vs CCCC Comparison
USGO vs CCCC Comparison
Compare USGO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- CCCC
- Stock Information
- Founded
- USGO 2015
- CCCC 2015
- Country
- USGO United States
- CCCC United States
- Employees
- USGO N/A
- CCCC N/A
- Industry
- USGO Precious Metals
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- USGO Basic Materials
- CCCC Health Care
- Exchange
- USGO Nasdaq
- CCCC Nasdaq
- Market Cap
- USGO 117.3M
- CCCC 104.4M
- IPO Year
- USGO 2023
- CCCC 2020
- Fundamental
- Price
- USGO $8.37
- CCCC $2.10
- Analyst Decision
- USGO Strong Buy
- CCCC Buy
- Analyst Count
- USGO 1
- CCCC 3
- Target Price
- USGO $26.50
- CCCC $12.00
- AVG Volume (30 Days)
- USGO 31.1K
- CCCC 1.6M
- Earning Date
- USGO 08-12-2025
- CCCC 08-04-2025
- Dividend Yield
- USGO N/A
- CCCC N/A
- EPS Growth
- USGO N/A
- CCCC N/A
- EPS
- USGO N/A
- CCCC N/A
- Revenue
- USGO N/A
- CCCC $39,783,000.00
- Revenue This Year
- USGO N/A
- CCCC N/A
- Revenue Next Year
- USGO N/A
- CCCC N/A
- P/E Ratio
- USGO N/A
- CCCC N/A
- Revenue Growth
- USGO N/A
- CCCC 98.56
- 52 Week Low
- USGO $5.00
- CCCC $1.09
- 52 Week High
- USGO $14.46
- CCCC $7.36
- Technical
- Relative Strength Index (RSI)
- USGO 43.70
- CCCC 57.47
- Support Level
- USGO $8.18
- CCCC $2.15
- Resistance Level
- USGO $9.11
- CCCC $2.53
- Average True Range (ATR)
- USGO 0.40
- CCCC 0.24
- MACD
- USGO 0.02
- CCCC -0.01
- Stochastic Oscillator
- USGO 53.37
- CCCC 35.58
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.